$ABT (Abbott Laboratories)

$ABT {{ '2016-07-20T14:33:53+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings Infographics: Q2 2016 highlights.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$ABT {{ '2017-07-17T12:36:21+0000' | timeago}} • Announcement

$ABT is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share of Preferred Stock. The offer will expire at 11:59 pm, NYC time, on Aug 11, 2017. There is no financing condition to the offer.

$ABT {{ '2017-07-13T12:23:21+0000' | timeago}} • Announcement

$ABT and Bigfoot Biomedical agreed to develop and commercialize diabetes management systems, integrating $ABT's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States. $ABT will provide Bigfoot with the next generation of its FreeStyle Libre glucose sensing technology.

$ABT {{ '2017-06-29T17:53:11+0000' | timeago}} • Announcement

$ABT announced the Health Canada license of its FreeStyle Libre Flash Glucose Monitoring System, a glucose sensing technology for adults with diabetes. This system eliminates the need for routine finger sticks or finger stick calibration, and reads glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days.

$ABT {{ '2017-06-16T10:42:39+0000' | timeago}} • Announcement

$ABT announced that the Sekisui CP3000 coagulation system, a fully automated analyzer that tests bleeding and clotting function in blood, is now available in Europe, the Middle East, and Asia Pacific.

$ABT {{ '2017-06-09T14:38:24+0000' | timeago}} • Announcement

The Board of $ABT declared a quarterly common dividend of 26.5 cents per share. The dividend is payable Aug. 15, 2017, to shareholders of record as on July 14, 2017.

$ABT {{ '2017-04-19T14:38:44+0000' | timeago}} • Webcast

$ABT said its results were slightly impacted by the demonetization in India and the impact is now diminishing. With respect to the Goods and Services Tax, the government is looking at implementing a new tax scheme. If this is done, it could have an impact on the way distributors manage inventory. $ABT is monitoring this situation.

$ABT {{ '2017-04-19T14:16:27+0000' | timeago}} • Webcast

$ABT said its Nutrition business is driven by emerging markets and generates solid profit and cash flow. In Pharma, the branded generic business is in strong position and the company is focused on markets where high double digit growth exists. Diagnostics is launching a huge range of new systems and products. $ABT is pleased with its portfolio.

$ABT {{ '2017-04-19T13:56:43+0000' | timeago}} • Webcast

$ABT said there are some steps pending for the closure of its merger with $ALR. $ALR has to file its Form 10-K while $ABT has to divest a couple of its businesses to gain regulatory approvals. $ABT expects to close the transaction by 3Q17-end. Some businesses will be divested after the merger and the amount of sales and profits will change.

$ABT {{ '2017-04-19T12:20:16+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphics: Q1 2017 highlights

$ABT {{ '2017-04-19T12:10:04+0000' | timeago}} • Announcement

$ABT continues to expect 2017 EPS from continuing operations of $0.92-1.02, including intangible amortization and integration expenses related to the acquisition of St. Jude Medical. Excluding specified items, projected full-year 2017 adjusted EPS from continuing operations remains unchanged at $2.40-2.50.

$ABT {{ '2017-04-19T12:07:45+0000' | timeago}} • Announcement

$ABT reported a 32.5% jump in 1Q17 earnings driven by gain from the sale of the AMO business. Net income rose to $419MM or $0.24 per share from $316MM or $0.21 per share last year. Adjusted EPS increased to $0.48 from $0.41. Net sales grew to $6.34Bil from $4.89Bil. On a comparable operational basis, worldwide sales increased 3.2%.

$JNJ {{ '2017-02-27T14:41:59+0000' | timeago}} • Announcement

$JNJ completed the acquisition of Abbott Medical Optics (AMO), a subsidiary of $ABT. The all-cash $4.325Bil acquisition includes ophthalmic products in 3 areas of patient care: cataract surgery, laser refractive surgery and consumer eye health. The combined will operate under the brand name Johnson & Johnson Vision.

$ABT {{ '2017-02-21T18:13:27+0000' | timeago}} • Announcement

$ABT commenced offers to exchange all validly tendered and accepted notes of the following series issued by St. Jude Medical, LLC for notes to be issued by $ABT. The exchange offers and consent solicitations will expire on March 20, 2017, unless extended or terminated.

$ABT {{ '2017-02-17T17:40:09+0000' | timeago}} • Announcement

$ABT's BoD declared a quarterly common dividend of 26.5 cents per share. The cash dividend is payable on May 15, 2017, to shareholders of record at the close of business on Apr. 14, 2017.

$ABT {{ '2017-02-02T18:24:08+0000' | timeago}} • Announcement

$ABT's new molecular test, the Abbott RealTime ZIKA test, receives commercial authorization from the U.S. Food and Drug Administration. This test helps to detect Zika virus in whole blood samples for emergency use.

$ABT {{ '2017-02-01T15:35:32+0000' | timeago}} • Announcement

$ABT announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for both the Assurity MRI pacemaker and the Tendril MRI pacing lead.

$ABT {{ '2017-01-25T14:51:08+0000' | timeago}} • Webcast

$ABT stated that in China market conditions continue to remain challenging. The company expects its performance in China to improve going through the year. Outside of China, the company added that there has been good performance in Latin America and Southeast Asia.

$ABT {{ '2017-01-25T14:36:42+0000' | timeago}} • Webcast

$ABT said it is forecasting a loss of about $15MM on the exchange gain loss line of the P&L for FY17 and is forecasting about $45MM of non-operating expenses. Additionally for 1Q17, the company is forecasting an adjusted GM ratio of about 59.5% of sales, adjusted R&D investment of about 8% of sales and adjusted SG&A expense of around 33% of sales.

$ABT {{ '2017-01-25T14:24:54+0000' | timeago}} • Webcast

$ABT said that in Diagnostics, the company achieved above market sales growth in 2016 and initiated the global launch of Alinity, the next generation diagnostic systems. On an overall company basis, the company expects annual pre-tax synergies of $500MM by 2020.

Recent Transcripts

MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
PTX (Pernix Therapeutics Holdings, Inc.)
Monday, May 15 2017 - 8:30pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Wednesday, May 10 2017 - 9:00pm
MYL (Mylan N.V.)
Wednesday, May 10 2017 - 2:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
INCY (Incyte Corporation)
Thursday, May 4 2017 - 2:00pm
PCRX (Pacira Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
LIVN (LivaNova PLC)
Wednesday, May 3 2017 - 1:00pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
INVA (Innoviva, Inc.)
Thursday, April 27 2017 - 9:00pm
CYTK (Cytokinetics, Incorporated)
Thursday, April 27 2017 - 8:30pm
ABAX (Abaxis, Inc.)
Thursday, April 27 2017 - 8:15pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm
KO (The Coca-Cola Company)
Tuesday, April 25 2017 - 1:00pm
ABT (Abbott Laboratories)
Wednesday, April 19 2017 - 1:00pm

AlphaGraphics you may like